US scientists have discovered a new gene therapy technique that is able to modify prostate cancer cells so that a patient’s body attacks and kills them.
According to a report by BBC, the technique causes the tumour cells in the body to self-destruct, giving it the name ‘suicide gene therapy’.
Their research found a 20% improvement in survival in patients with prostate cancer five years after treatment.
A cancer expert said more research was needed to judge its effectiveness.
Prostate cancer is the most common cancer in men in the UK with more than 41,000 diagnosed each year.
The study, led by researchers from Houston Methodist Hospital in Texas, appears to show that this ‘suicide gene therapy’, when combined with radiotherapy, could be a promising treatment for prostate cancer in the future.
The technique involves the cancer cells being genetically modified so that they signal a patient’s immune system to attack them.
Usually, the body does not recognise cancer cells as the enemy because they have evolved from normal healthy cells.
Unlike an infection, which the body reacts against, the immune system does not react to kill off the offending cancer cells.
Using a virus to carry the gene therapy into the tumour cells, the result is that the cells self-destruct, alerting the patient’s immune system that it is time to launch a massive attack.
In two groups of 62 patients, one group received the gene therapy twice and the other group – who all had more aggressive prostate cancer – received the treatment three times.
Both groups also received radiotherapy.
Survival rates after five years were 97% and 94%. Although there was no control group in this study, the researchers said the results showed a five to 20% improvement on previous studies of prostate cancer treatment.
And cancer biopsy tests performed two years after the trial were found to be negative in 83% and 79% of the patients in the two groups.
Dr Brian Butler, from Houston Methodist Hospital in Texas, said it could change the way that cancer is treated.
Kevin Harrington, professor of biological cancer therapies at The Institute of Cancer Research, London, said the results were “very interesting” but more research was needed.
Send news and suggestions to firstname.lastname@example.org